Laboratorios Lesvi is Neuraxpharm’s manufacturing facility for Finished Dosage Forms (FDF) in Spain Barcelona and Dusseldorf – May 4, 2023 – Neuraxpharm Group (Neuraxpharm), the leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announces that it has rebranded Laboratorios Lesvi to create Neuraxpharm Pharmaceuticals S.L. Read more…
Belgium team to expand under Country Manager, Dr Pierre-Hervé Brun, providing CNS treatments to patients Brussels and Düsseldorf – January 24, 2023 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announces the establishment of Neuraxpharm Belgium to cover Belgium and Luxembourg, completing its presence […]
Europe’s leading central nervous system specialty company strengthens its management team in Ireland and reinforces its growth strategy Dusseldorf and Barcelona, March 15, 2022 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the central nervous system (CNS), today announces that Tom Coogan has been appointed Country Manager for Ireland. The appointment reinforces […]
Acquisition of Brain Therapeutics with operations in Greece, Cyprus and the Balkan countries Dusseldorf and Barcelona, March 8th, 2022 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the central nervous system (CNS), today announces the expansion of its business in Southeast Europe through the acquisition of Brain Therapeutics, a CNS-focused marketing and distribution […]